Whole-body diffusion-weighted MRI is a new-generation imaging tool for detecting prostate cancer. The extent of bone metastasis and the presence of visceral metastasis on whole-body diffusion-weighted MRI according to METastasis Reporting and Data System for Prostate Cancer (MET-RADS-P) were associated with a lower cancer-specific survival in castration-resistant prostate cancer. Furthermore, whole-body diffusion-weighted MRI facilitates identification of oligo-progressive lesions, which can be targets for loco-regional radiotherapy. MET-RADS-P score of whole-body diffusion-weighted MRI can be an imaging biomarker for castration-resistant prostate cancer in predicting clinical course, and identifying oligo-progressive lesions as targets for loco-regional ablative therapy.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords